Vitamin D and primary hyperparathyroidism (PHPT)

Annales d'Endocrinologie

Volumn 73, Issue 3, 2012, Pages 165-169

  Souberbielle, Jean Claude ^a,b   Bienaimé, Frank ^a,b   Cavalier, Etienne ^c   Cormier, Catherine ^b,d  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d Hôpital Cochin AP HP ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIFEDIOL; CALCITRIOL; CALCIUM; COLECALCIFEROL; PARATHYROID HORMONE; VITAMIN D;

CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; HUMAN; PARATHYROID HORMONE BLOOD LEVEL; PHENOTYPE; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; SHORT SURVEY; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

CLINICAL TRIALS AS TOPIC; COMORBIDITY; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPARATHYROIDISM, PRIMARY; KIDNEY; MALE; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; POSTMENOPAUSE; PRACTICE GUIDELINES AS TOPIC; REAGENT KITS, DIAGNOSTIC; REFERENCE VALUES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84863842730     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2012.04.008     Document Type: Short Survey

References (50)

1. Holick M. Vitamin D deficiency. N Engl J Med 2007, 357(3):266-281.
2. Lundgren E., Hagström E.G., Lundin J., Winnerbäck K.L., Ross J., Ljunghall S., et al. Primary hyperparathydoidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago. World J Surg 2002, 26(8):931-936.
3. Eastell R., Arnold A., Brandi M.L., Brown E.M., D'Amour P., Hanley D.A., et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94(2):340-350.
4. Silverberg S.J., Lewiecki E.M., Mosekilde L., Peacock M., Rubin M.R. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94(2):351-365.
5. Udelsman R., Pasieka J.L., Sturgeon C., Young J.E., Clark O.H. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94(2):366-372.
6. Khan A., Grey A., Shoback D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94(2):373-381.
7. Bilezikian J.P., Khan A.A., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009, 94(2):335-339.
8. Christensen S.E., Nissen P.H., Vestergaard P., Heickendorff L., Rejnmark L., Brixen K., et al. Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism. Eur J Endocrinol 2008, 159(6):719-727.
9. Silverberg S.J., Shane E., Dempster D.W., Bilezikian J.P. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 1999, 107(6):561-567.
10. Brown A.J., Dusso A., Slatopolsky E. Vitamin D. Am J Physiol 1999, 277(2 Pt 2):F157-F175.
11. Henry H.L., Norman A.W. Vitamin D: metabolism and biological actions. Annu Rev Nutr 1984, 4:493-520.
12. Kebebew E., Duh O.Y., Clark O.H. Tertiary hyperparathyroidism: histologic patterns of disease and results of parathyroidectomy. Arch Surg 2004, 139(9):974-977.
13. Rivkees S.A., El-Hajj-Fuleihan G., Brown E.M., Crawford J.D. Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemmic rickets. J Clin Endocrinol Metab 1992, 75(6):1514-1518.
14. Akerström G., Rudbeerg C., Grimelius L., Bergström R., Johansson H., Ljunghall S., et al. Histologic parathyroid abnormalities in an autopsy series. Hum Pathol 1986, 17(5):520-527.
15. Yano S., Sugimoto T., Tsukamoto T., Chihara K., Kobayashi A., Kitazawa S., et al. Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. Eur J Endocrinol 2003, 148(4):403-411.
16. Brown A.J., Zhong M., Finch J., Ritter C., McCracken R., Morrissey J., et al. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol 1996, 270(3 Pt 2):F454-F460.
17. Arnold A., Shattuck T.M., Mallya S.M., Krebs L.J., Costa J., Gallagher J., et al. Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res 2002, 17(Suppl. 2):N30-N36.
18. Lauter K., Arnold A. Analysis of CYP27B1, encoding 25-hydroxyvitamin D-1alpha-hydroxylase, as a candidate tumor suppressor gene in primary and severe secondary/tertiary hyperparathyroidism. J Bone Miner Res 2009, 24(1):102-104.
19. Samander E.H., Arnold A. Mutational analysis of the vitamin D receptor does not support its candidacy as a tumor suppressor gene in parathyroid adenomas. J Clin Endocrinol Metab 2006, 91(12):5019-5021.
20. Carling T., Kindmark A., Hellman P., Lundgren E., Ljunghall S., Rastad J., et al. Vitamin D receptor genotypes in primary hyperparathyroidism. Nat Med 1995, 1(12):1309-1311.
21. Kobayashi T., Sugimoto T., Kobayashi A., Chihara K. Vitamin D receptor genotype is associated with cortical bone loss in Japanese patients with primary hyperparathyroidism. Endocr J 1998, 45(1):123-125.
22. Corbetta S., Vicentini L., Ferrero S., Lania A., Mantovani G., Cordella D., et al. Activity and function of the nuclear factor kappaB pathway in human parathyroid tumors. Endocr Relat Cancer 2005, 12(4):929-937.
23. Tan X., Wen X., Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 2008, 19(9):1741-1752.
24. Boudou P., Ibrahim F., Cormier C., Sarfati E., Souberbielle J.C. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest 2006, 29(6):511-515.
25. Moosgaard B., Vestergaard P., Heickendorff L., Melsen F., Christiansen P., Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 2005, 63(5):506-513.
26. Rao D.S., Honasoge M., Divine G.W., Phillips E.R., Lee M.W., Ansari M.R., et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 2001, 86(5):2328.
27. Moosgaard B., Vestergaard P., Heickendorff L., Melsen F., Christiansen P., Mosekilde L. Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur J Endocrinol 2006, 155(2):237-244.
28. Raef H., Ingemansson S., Sobhi S., Sultan A., Ahmed M., Chaudhry M. The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region. J Endocrinol Invest 2004, 27(9):807-812.
29. Ozbey N., Erbil Y., Ademoĝlu E., Ozarmaĝan S., Barbaros U., Bozbora A. Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World J Surg 2006, 30(3):321-326.
30. Moosgaard B., Christensen S.E., Vestergaard P., Heickendorff L., Christiansen P., Mosekilde L. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf) 2008, 68(5):707-715.
31. Inoue Y., Kaji H., Hisa I., Tobimatsu T., Naito J., Iu M.F., et al. Vitamin D status affects osteopenia in postmenopausal patients with primary hyperparathyroidism. Endocr J 2008, 55(1):57-65.
32. Nordenström E., Westerdahl J., Lindergård B., Lindblom P., Bergenfelz A. Multifactorial risk profile for bone fractures in primary hyperparathyroidism. World J Surg 2002, 26(12):1463-1467.
33. Pradeep P.V., Mishra A., Agarwal G., Agarwal A., Verma A.K., Mishra S.K. Long-term outcome after parathyroidectomy in patients with advanced primary hyperparathyroidism and associated vitamin D deficiency. World J Surg 2008, 32(5):829-835.
34. Untch B.R., Barfield M.E., Dar M., Dixit D., Leight G.S., Olson J.A. Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism. Surgery 2007, 142(6):1022-1026.
35. Stewart Z.A., Blackford A., Somervell H., Friedman K., Garrett-Mayer E., Dackiw A.P., et al. 25-hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery 2005, 138(6):1018-1025. [discussion 1025-6].
36. Kantorovitch V., Gacad M.A., Seeger L.L., Adams J.S. Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. J Clin Endocrinol Metab 2000, 85(10):3541-3543.
37. Grey A., Lucas J., Horne A., Gamble G., Davidson J.S., Reid I.R. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 2005, 90(4):2122-2126.
38. Grubbs E.G., Rafeeq S., Jimenez C., Feng L., Lee J.E., Evans D.B., et al. Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial?. Surgery 2008, 144(6):852-858. [discussion 858-9].
39. Tucci J.R. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol 2009, 161(1):189-193.
40. Isidro M.L., Ruano B. Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine 2009, 36(2):305-310.
41. Nussbaum S., Zahradnik R., Lavigne J., Brennan G., Nozawa-Ung K., Kim L., et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987, 33:1364-1367.
42. Blind E., Schmidt-Gayk H., Scharla S., Flentje D., Fischer S., Göhring U., et al. Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a mid-region assay. J Clin Endocrinol Metab 1988, 67:353-360.
43. Endres D., Villanueva R., Sharp C., Singer F. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem 1991, 37:162-168.
44. Ratcliffe W., Heath D., Ryan M., Jones S. Performance and diagnostic application of a two-site immunometric assay for parathyrin in serum. Clin Chem 1989, 35:1957-1961.
45. Gao P., Scheibel S., D'Amour P., John M., Rao S., Schmidt-Gayk H., et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implication for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001, 16:605-614.
46. Mithal A., Wahl D.A., Bonjour J.P., et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009, 11:1807-1820.
47. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001, 22(4):477-501.
48. Souberbielle J.C., Cormier C., Kindermans C., Gao P., Cantor T., Forette F., et al. Vitamin D status and redefining serum parathyroid hormone reference range. J Clin Endocrinol Metab 2001, 86:3086-3090.
49. Cavalier E., Delanaye P., Vranken L., et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant 2012, 27:1950-1956.
50. Cavalier E., Rozet E., Gadisseur R., et al. Measurement uncertainty of 25-OH vitamin D determination with different commercially available kits: impact on the clinical cut-offs. Osteoporos Int 2010, 31:1047-1051.